264 related articles for article (PubMed ID: 19117505)
1. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
Ahlquist T; Lind GE; Costa VL; Meling GI; Vatn M; Hoff GS; Rognum TO; Skotheim RI; Thiis-Evensen E; Lothe RA
Mol Cancer; 2008 Dec; 7():94. PubMed ID: 19117505
[TBL] [Abstract][Full Text] [Related]
2. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
3. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability.
Muto Y; Maeda T; Suzuki K; Kato T; Watanabe F; Kamiyama H; Saito M; Koizumi K; Miyaki Y; Konishi F; Alonso S; Perucho M; Rikiyama T
BMC Cancer; 2014 Jun; 14():466. PubMed ID: 24964857
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
[TBL] [Abstract][Full Text] [Related]
6. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.
Lind GE; Thorstensen L; Løvig T; Meling GI; Hamelin R; Rognum TO; Esteller M; Lothe RA
Mol Cancer; 2004 Oct; 3():28. PubMed ID: 15476557
[TBL] [Abstract][Full Text] [Related]
7. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
8. The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer.
Samowitz WS; Curtin K; Wolff RK; Albertsen H; Sweeney C; Caan BJ; Ulrich CM; Potter JD; Slattery ML
Genes Chromosomes Cancer; 2008 Oct; 47(10):835-44. PubMed ID: 18615680
[TBL] [Abstract][Full Text] [Related]
9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
10. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.
Lind GE; Kleivi K; Meling GI; Teixeira MR; Thiis-Evensen E; Rognum TO; Lothe RA
Cell Oncol; 2006; 28(5-6):259-72. PubMed ID: 17167179
[TBL] [Abstract][Full Text] [Related]
11. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
Ye C; Shrubsole MJ; Cai Q; Ness R; Grady WM; Smalley W; Cai H; Washington K; Zheng W
Oncol Rep; 2006 Aug; 16(2):429-35. PubMed ID: 16820927
[TBL] [Abstract][Full Text] [Related]
13. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
15. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
16. Analysis of molecular alterations in laterally spreading tumors of the colorectum.
Sugai T; Habano W; Takagi R; Yamano H; Eizuka M; Arakawa N; Takahashi Y; Yamamoto E; Kawasaki K; Yanai S; Ishida K; Suzuki H; Matsumoto T
J Gastroenterol; 2017 Jun; 52(6):715-723. PubMed ID: 27704264
[TBL] [Abstract][Full Text] [Related]
17. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
[TBL] [Abstract][Full Text] [Related]
18. SLC5A8 gene, a transporter of butyrate: a gut flora metabolite, is frequently methylated in African American colon adenomas.
Brim H; Kumar K; Nazarian J; Hathout Y; Jafarian A; Lee E; Green W; Smoot D; Park J; Nouraie M; Ashktorab H
PLoS One; 2011; 6(6):e20216. PubMed ID: 21687703
[TBL] [Abstract][Full Text] [Related]
19. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
[TBL] [Abstract][Full Text] [Related]
20. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
